白塞病葡萄膜炎的危险因素、临床特征与治疗
本文综述白塞病葡萄膜炎的独立临床集群特征、遗传与感染相关易感因素,以及以糖皮质激素联合免疫调节药物(抗TNF制剂、干扰素、环孢素、硫唑嘌呤等)为主流的治疗方案,并指出未来研究方向为比较免疫调节药物疗效及基于分子异质性识别最适合特定药物的亚组。
要点
- 眼部白塞病主要表现为葡萄膜炎,属独立临床集群,与其他系统受累关联可能性低。
- HLA-B51、HLA-A26、HLA-B15、HLA-B5701等位基因及IL-23/IL-17通路、TNF信号、模式识别受体系统变异 confer 遗传易感性。
- 复发-缓解病程显著,预防复发是主要治疗目标,主流方案为糖皮质激素联合免疫调节药物。
核心结论
- 眼部白塞病以葡萄膜炎为主要表现,是独立临床集群,与其他系统受累关联可能性低。
- 疾病发病机制为多因素,遗传与感染因素在免疫遗传易感个体中相互作用。
- 预防复发是主要治疗目标,糖皮质激素联合免疫调节药物为主流方案。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 近期发现白塞病存在独立临床集群,眼部白塞病为其中之一,与肠道、心血管或中枢神经系统受累关联可能性低。
- 散发病例中HLA-B51、HLA-A26、HLA-B15、HLA-B5701等HLA基因是遗传易感性关键组分。
- HLA区域外,白细胞介素(IL)-23/IL-17通路、肿瘤坏死因子(TNF)信号和模式识别受体系统相关易感变异被识别。
- 链球菌(Streptococcus sanguinis)、结核分枝杆菌(Mycobacterium tuberculosis)和单纯疱疹病毒(HSV)等微生物感染与免疫遗传易感个体中疾病触发相关。
关键数值与推荐
- 眼部白塞病呈显著复发-缓解病程,预防复发为主要治疗目标。
- 糖皮质激素联合免疫调节药物(如抗TNF制剂、干扰素和传统免疫抑制剂如环孢素、硫唑嘌呤)为主流方案。
- 未来研究可能聚焦于比较免疫调节药物有效性,并基于分子异质性识别最适合特定药物的亚组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Behçet's disease is a systemic vasculitis frequently associated with intraocular inflammation. Recent findings identified independent clinical clusters in Behçet's disease, each involving distinct combinations of affected organs. Ocular Behçet's disease, mainly manifested as uveitis, is characterized as an independent cluster with a low likelihood of association with other system involvements, such as intestinal, cardiovascular, or central nervous system. A prevailing theory suggests that the pathogenesis of the disease is multifactorial, where a variety of genetic and infectious agents may interact with each other to cause the disease. Among sporadic cases, the human leukocyte antigen (HLA) genes, including HLA-B51, HLA-A26, HLA-B15, and HLA-B5701, have been found to be a key component conferring genetic susceptibility. Outside the HLA region, a set of susceptibility variants are identified, closely related to interleukin (IL)-23/IL-17 pathway, tumor necrosis factor (TNF) signaling, and pattern recognition receptor systems. Microbial infections, such as Streptococcus sanguinis, Mycobacterium tuberculosis, and Herpes simplex virus (HSV), are linked to play the triggering of disease in immunogenetically predisposed individuals. Clinically, due to the notable relapsing-remitting course of ocular Behçet's disease, the prevention of recurrent attack would be the primary treatment goal. Combination of corticosteroids and immunomodulatory drugs, such as anti-TNF agents, interferon, and conventional immunosuppressants (e.g. cyclosporine, azathioprine), have been the mainstream regimen for the disease. Future research may focus on comparing the effectiveness of immunomodulatory drugs and identifying the most suitable subgroups for a specific drug on the basis of the knowledge of the molecular heterogeneity of the disease.
引用
- Zhong Z, Su G, Yang P, et al. Risk factors, clinical features and treatment of Behçet's disease uveitis. Prog Retin Eye Res. 2023. PMID: 37734442. doi:10.1016/j.preteyeres.2023.101216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。